PMID- 32194844
OWN - NLM
STAT- MEDLINE
DCOM- 20210330
LR  - 20210330
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 10
IP  - 7
DP  - 2020
TI  - One-pot synthesis of a microporous organosilica-coated cisplatin nanoplatform for 
      HIF-1-targeted combination cancer therapy.
PG  - 2918-2929
LID - 10.7150/thno.41077 [doi]
AB  - Nanoparticle formulations have proven effective for cisplatin delivery. However, 
      the development of a versatile nanoplatform for cisplatin-based combination 
      cancer therapies still remains a great challenge. Methods: In this study, we 
      developed a one-pot synthesis method for a microporous organosilica shell-coated 
      cisplatin nanoplatform using a reverse microemulsion method, and explored its 
      application in co-delivering acriflavine (ACF) for inhibiting hypoxia-inducible 
      factor-1 (HIF-1). Results: The resulting nanoparticles were tunable, and they 
      could be optimized to a monodisperse population of particles in the desired size 
      range (40-50 nm). In addition, organic mPEG2000-silane and tetrasulfide 
      bond-bridged organosilica were integrated into the surface and silica matrix of 
      nanoparticles for prolonged blood circulation and tumor-selective 
      glutathione-responsive degradation, respectively. After reaching the tumor sites, 
      cisplatin induced cancer cell death and activated HIF-1 pathways, resulting in 
      acquired drug resistance and tumor metastasis. To address this issue, ACF was 
      co-loaded with cisplatin to prevent the formation of HIF-1alpha/beta dimers and suppress 
      HIF-1 function. Hence, the efficacy of cisplatin was improved, and cancer 
      metastasis was inhibited. Conclusion: Both in vitro and in vivo results suggested 
      that this core-shell nanostructured cisplatin delivery system represented a 
      highly efficacious and promising nanoplatform for the synergistic delivery of 
      combination therapies involving cisplatin.
CI  - (c) The author(s).
FAU - Zhang, Xiaojuan
AU  - Zhang X
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - He, Chuanchuan
AU  - He C
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Liu, Xiaoguang
AU  - Liu X
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Chen, Yan
AU  - Chen Y
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Zhao, Pengxuan
AU  - Zhao P
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Chen, Chen
AU  - Chen C
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Yan, Ruicong
AU  - Yan R
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Li, Minsi
AU  - Li M
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Fan, Ting
AU  - Fan T
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Altine, Bouhari
AU  - Altine B
AD  - Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Yang, Tan
AU  - Yang T
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Lu, Yao
AU  - Lu Y
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
FAU - Lee, Robert J
AU  - Lee RJ
AD  - Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, 
      OH 43210, USA.
FAU - Gai, Yongkang
AU  - Gai Y
AD  - Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430022, China.
AD  - Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
FAU - Xiang, Guangya
AU  - Xiang G
AD  - School of Pharmacy, Tongji Medical College, Huazhong University of Science and 
      Technology, Wuhan 430030, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200203
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Hif1a protein, mouse)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 1T3A50395T (Acriflavine)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - A549 Cells
MH  - Acriflavine/*pharmacology
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Cisplatin/*pharmacology
MH  - Drug Carriers/*chemical synthesis
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors
MH  - Mice
MH  - Nanoparticles/*chemistry
MH  - Neoplasms/*drug therapy
MH  - Silicon Dioxide/*chemistry
PMC - PMC7053205
OTO - NOTNLM
OT  - HIF-1
OT  - acriflavine
OT  - cisplatin
OT  - combination therapy
OT  - nanoparticle
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/03/21 06:00
MHDA- 2021/03/31 06:00
PMCR- 2020/01/01
CRDT- 2020/03/21 06:00
PHST- 2019/10/11 00:00 [received]
PHST- 2020/01/15 00:00 [accepted]
PHST- 2020/03/21 06:00 [entrez]
PHST- 2020/03/21 06:00 [pubmed]
PHST- 2021/03/31 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - thnov10p2918 [pii]
AID - 10.7150/thno.41077 [doi]
PST - epublish
SO  - Theranostics. 2020 Feb 3;10(7):2918-2929. doi: 10.7150/thno.41077. eCollection 
      2020.